

Dingwall, Dave—Cont.

- Free trade, Canada-United States negotiations, 14:25
 Gagné, references, 11:41
 Generic drugs, 5:26, 40; 8:19, 64; 10:16; 11:41, 43; 12:46;
 14:10-1; 15:57; 16:76-82
 Health care, 11:58-9; 12:67-9; 14:23; 15:21-2, 93
 High technology centres, 5:38-9, 45
 Manitoba, 15:92-3
 Multiple sclerosis, 8:8
 Multiple Sclerosis Society of Ottawa-Carleton, 8:9-10
 National Anti-Poverty Organization, 12:55
 National Biotechnology Advisory Committee, 12:45
 National Federation of Nurses' Unions, 9:29-30
 National Health and Welfare Department, M., 13:32-5
 Ontario, 17:19-21
 Patent Act (amdt.)(Bill C-22), 3:5, 12-4, 23, 25, 27-9, 34-6, 52-5,
 57, 64-6, 73, 74; 4:6, 8-9, 12-4, 16-8, 21, 23, 26-7, 29-34; 5:8-9,
 14-6, 26-7, 31-3, 38-41, 45-9; 6:9-15, 20-6, 28, 38-41, 52-4, 63-5,
 72, 77-8; 7:7-10, 19; 8:8-10, 17, 19-21, 32-3, 38-41, 49, 53-4, 64;
 9:5-6, 9, 13-4, 22-3, 27-30, 45-6; 10:12-6, 20, 23-5, 29-40, 46,
 49-50; 11:5, 8-11, 17, 23-6, 32-5, 38, 41-3, 46, 56-9, 69-71, 77,
 80-1; 12:7-10, 20-2, 32-5, 45-7, 55-7, 62, 66-9, 74; 13:10-3, 22-5,
 32-5, 41-3; 14:5-6, 10-3, 20, 23-6, 37-41; 15:9-11, 21-3, 33-6,
 50-2, 57-9, 63, 66, 68, 70-1, 75-9, 92-4, 100; 16:10-6, 19-20,
 24-9, 32-3, 35, 39-42, 45-54, 56-7, 60-2, 64-8, 71-3, 75-85, 87;
 17:18-22, 24-44
 Patent Co-operation Treaty, 16:32-3
 Procedure and Committee business
 Bills, 4:16; 10:49-50; 11:32-4, 80-1; 17:33, 43-4
 M. (White), 4:8-9; 5:47-9
 Amdt. (McCurdy), 4:31-4
 M. (Orlikow), 11:35
 Amdt. (Tardif), 11:38
 M. (Orlikow), 15:10
 Briefs, 3:5, 23; 5:47-8; 14:5-6
 Chairman, 4:12-3
 Information, 3:12, 14, 52-3, 57, 64-5; 6:25, 38; 8:20; 14:37-8
 Meetings, 15:100; 16:10
 M. (White), 4:8, 16
 M., 4:34
 Members, 4:9; 9:5-6, 9, 22
 M., 9:23
 Motions, 5:8
 Proceedings, M., 5:9
 Questioning of witnesses, 3:52; 6:11-2
 Witnesses, 7:7, 19; 8:49; 10:20, 50; 14:5
 M. (White), 4:6, 8-9, 13, 16-7, 21, 23; 6:9-10; 8:32-3; 9:5-6, 9
 Amdt. (Kempling), 4:26-7
 Amdt. (McCurdy), 4:29-30
 M. (Orlikow), 15:70
 Public Service Alliance of Canada, 10:23-5
 Quebec Federation of Senior Citizens, 12:20
 Regulations and Other Statutory Instruments Standing Joint
 Committee, 16:32-3
Rise and Fall of Montreal, The, 10:12
 Roache, references, 14:37
 Saskatchewan, 11:23-5, 69, 70; 12:69
 Senior citizens, 3:73; 12:20
 Smith, Kline and French Canada Ltd., 10:12; 14:37-40

Disabled and handicapped

- Drug costs, Bill C-22 increasing, 15:71-2, 76-7, 79-81, 84
 Employment barriers, 15:79
 Review boards, witnesses appearing, barriers, 15:78-9

Diseases

- Infectious, research/education, need, 15:5-7, 9, 11

Diseases—Cont.

- Infectious, research/education, need—*Cont.*
 AIDS, toxic shock syndrome, etc., 15:11-2
 Malaria, sleeping sickness, etc., 15:15-6
 Sexually transmitted, pharmaceutical industry contribution,
 15:12-3
 Immigration, contributing, 15:16
 See also Alzheimer's disease; Diabetes; Kidney disease; Ojibway
 Nation; Orphan diseases
 DNA see Bio-tech industry—Research and development, Recombinant
 DNA research
 Documents see Appendices; Procedure and Committee business
 Drug compliance see Drugs and pharmaceuticals
 Drug Export Amendments Act see Drugs and
 pharmaceuticals—United States
 Drug patents, 6:15-6; 17:45-6, 51
 Abolishing, Restrictive Trade Practices Commission proposal, 6:49;
 11:6, 10-1
 Sweden/Denmark examples, 11:15
 Applications, 16:45-6, 53-7
 Annual reports, patent lists, publishing, 16:40-4
 Canadian jurisprudence applying, 16:27-9
 Fees, 16:52-3
 Governor in Council regulations, 16:31-2
 Inspection by public, 16:29, 35-7, 39-40, 42-3; 17:47-8
 Japanese system, comparing, 16:42, 44
 Patents agents register, 16:34-5
 Priority dates, invention, defining, 16:26-8, 34; 17:49-50
 Canadian Patent Office, role/duties, etc., 8:18, 28
 Copyright comparison, 8:24-5
 Defining, 6:5-6, 79; 8:25
 Eastman position, 8:23-4, 59-60
 First-to-file system, Bill C-22 instigating, 6:45-52
 Friedman quotation, 8:23
 Imports, protecting, 11:5
 International practices, 8:23, 52, 56-7
 Legislation, Bill C-22 effect, 6:6-11; 8:25; 12:6-7
 Innovation, limiting, 9:44
 Strayer decision, 12:58; 14:42, 67-8; 15:72
 Market forces, special case exemption, 11:67-8
 Monopolies, differentiating, 6:57-8; 11:15
 Price control, government interference, 8:17-8
 Processing timeframe, 1:11, 20
 Product vs process patent, Bill C-22 introducing, 1:13-4; 3:8; 6:7, 47;
 11:12-3; 16:17-8, 58, 61-3
 Orphan drug situation, 6:36
 Reverse onus, Bill C-22 reinstating, 16:58-62, 65; 17:48-9
 See also Biotechnology industry—Process patents affecting
 Returns to inventor, government insuring, Economic Council of
 Canada quotation, 8:20
 Revenues, use, 8:18
 See also Apotex; Biotechnology industry—Legislation—Patent law
 principles; Brand name drugs—Exclusivity period from imports;
 Compulsory licensing; Drugs and pharmaceuticals
 industry—Patents; Genetic animals; Plant-breeder rights;
 Universities—Research and development
 Drug plans, 8:13
 Access, 15% of Canadians not covered, 6:22, 62; 7:12; 8:12, 51, 54;
 9:46-7, 51-2; 10:21-2; 11:50; 12:21, 54, 56, 67-8, 70; 13:6, 18, 23;
 14:9, 11-2, 14, 28, 58
 Unemployment insurance recipients not covered, 11:54
 Alberta, 11:22